Below are the most recent publications written about "Cardiomyopathy, Hypertrophic" by people in Profiles.
-
Lewis GD, Garcia-Pavia P, Masri A, Merkely B, Nassif ME, Pe?a-Pe?a ML, Barriales-Villa R, Bilen O, Burroughs M, Claggett B, Costabel JP, de Barros Correia E, Dybro AM, Kulac IJ, Lakdawala NK, Mann A, Maron MS, McGinnis S, Nair A, Newlands C, Poulsen SH, Reant P, Schulze PC, Solomon SD, Wang A, Sohn R, Berhane I, Heitner SB, Jacoby DL, Kupfer S, Malik FI, Wohltman A, Fifer MA, Elliott PM. Exercise Performance With Aficamten vs Metoprolol in Obstructive Hypertrophic Cardiomyopathy: The MAPLE-HCM Randomized Clinical Trial. JAMA Cardiol. 2026 Aug 01; 11(8):736-746.
-
Schulz A, Maron MS, Peng LW, Maron BA, Amyar A, Ngo L, Olivotto I, Chan RH, Manning WJ, Rowin EJ, Nezafat R. Clinical Course and Predictors of Heart Failure in Asymptomatic Obstructive Hypertrophic Cardiomyopathy. J Am Heart Assoc. 2026 Jul 07; 15(13):e048066.
-
Dutta D, Kim Y, Ho CY, Seidman JG, Seidman CE, Craig R, Padr?n R. Thick filament molecular interfaces play a critical role in the pathogenesis of hypertrophic cardiomyopathy. Proc Natl Acad Sci U S A. 2026 Jul 07; 123(27):e2529234123.
-
Tower-Rader A, Masri A, Nassif ME, Abraham TP, Barriales-Villa R, Choudhury L, Cooper RM, Elliott PM, Maron MS, Olivotto I, Oreziak A, Owens AT, Solomon SD, Heitner SB, Jacoby DL, Kupfer S, Liu X, Malik FI, Melloni C, Simkins TJ, Wei J, Saberi S. Aficamten in symptomatic obstructive hypertrophic cardiomyopathy: the FOREST-HCM long-term study. Eur Heart J. 2026 Jun 23; 47(24):3120-3131.
-
Kramer CM, Kolm P, DiMarco JP, Desai MY, Ho CY, Kwong RY, Dolman SF, Desvigne-Nickens P, Geller N, Kim DY, Schulz-Menger J, Friedrich MG, Maron MS, Appelbaum E, Link MS, Francis GS, Greenberg B, Jerosch-Herold M, Piechnik S, Mahmod M, Raman B, Jacoby DL, Baldassare LA, White JA, Chiribiri A, Helms AS, Choudhury L, Michels M, Bradlow WM, Salerno M, Heitner SB, Masri A, Prasad SK, Mohiddin SA, Plein S, Madias C, Mahrholdt H, Bucciarelli-Ducci C, Nightingale AK, Weinsaft JW, Kim HW, McCann GP, van Rossum A, Germans T, Williamson EE, Geske JB, Flett AS, Dawson D, Mongeon FP, Olivotto I, Crean AM, Woo A, Owens AT, Anderson L, Sharma S, Biagini E, Newby DE, Andre F, Berry C, Kim B, Larose E, Abraham TP, Hays AG, Sherrid MV, Gelfand EV, Nagueh SF, Rimoldi O, Camici P, Elstein E, Autore C, Watkins H, Weintraub WS, Neubauer S. Predictors of Long-Term Outcomes in Hypertrophic Cardiomyopathy: The NHLBI HCM Registry. JAMA. 2026 Jun 09; 335(22):1959-1969.
-
Sayed A, Rowin EJ, Maron MS, Maron BJ. Demographics and clinical implications of a global bibliographic profile for the hypertrophic cardiomyopathy literature over 66 years (1960-2025). Int J Cardiol. 2026 Sep 15; 459:134571.
-
Fath AR, Aglan A, Naidu SS, Mader MJ, Chilton RJ, Elgendy IY, Maron MS, Rowin EJ. Mavacamten in Obstructive Hypertrophic Cardiomyopathy: National Insights on Access and Safety Profile From Real-World Data. J Am Heart Assoc. 2026 May 05; 15(9):e045994.
-
Veselka J, Gimeno R, Abraham TP, Barriales-Villa R, Claggett BL, Coats CJ, Hegde SM, Januzzi JL, Masri A, Miao ZM, Nassif ME, Olivotto I, Jacoby DL, Heitner SB, Kupfer S, Malik FI, Wohltman A, Maron MS. Efficacy of Aficamten in Hypertrophic Cardiomyopathy Patients With Very-High Left Ventricular Outflow Tract Gradients. Am J Cardiol. 2026 Jul 01; 270:133-141.
-
Rowin EJ, Siontis KC, Owens A, Olivotto I, Moussavi-Harami F, Michels M, Ommen SR, Garcia-Pavia P, Nazer B, Silver J, Wong TC, Estes NAM, Massera D, Ahamed H, Maron MS, Masri A. Atrial fibrillation in hypertrophic cardiomyopathy: A unique clinical entity requiring dedicated study. Heart Rhythm. 2026 08; 23(8):e1672-e1682.
-
Maron BJ, Ommen SR, Nishimura RA, McKenna WJ, Rakowski H, Sherrid MV, Olivotto I, Braunwald E, Maron MS. Evolution and Transformation of Hypertrophic Cardiomyopathy From a High Risk to a Treatable Low Mortality Disease With Contemporary Clinical Research Strategies. J Am Heart Assoc. 2026 Jun 16; 15(12):e047462.